HLA-A*02:01 Positive is altered in 0.06% of malignant solid tumor patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 11 clinical trials for malignant solid tumor, of which 8 are open and 3 are closed. Of the trials that contain HLA-A*02:01 Positive and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (3 open), 5 are phase 1/phase 2 (4 open), and 1 is phase 2 (0 open) [5].

HLA-A*02:01 Positive is altered in 0.11% of non-small cell lung carcinoma patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 10 clinical trials for non-small cell lung carcinoma, of which 9 are open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (4 open) and 5 are phase 1/phase 2 (5 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 7 clinical trials for acute myeloid leukemia, of which 7 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (2 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 7 clinical trials for melanoma, of which 2 are open and 5 are closed. Of the trials that contain HLA-A*02:01 Positive and melanoma as inclusion criteria, 3 are phase 1 (0 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 7 clinical trials for synovial sarcoma, of which 5 are open and 2 are closed. Of the trials that contain HLA-A*02:01 Positive and synovial sarcoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 6 clinical trials for hepatocellular carcinoma, of which 5 are open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and hepatocellular carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 2 are phase 1/phase 2 (2 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 6 clinical trials for multiple myeloma, of which 2 are open and 4 are closed. Of the trials that contain HLA-A*02:01 Positive and multiple myeloma as inclusion criteria, 3 are phase 1 (0 open) and 3 are phase 1/phase 2 (2 open) [5].

HLA-A*02:01 Positive is altered in 0.06% of ovarian carcinoma patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 6 clinical trials for ovarian carcinoma, of which 4 are open and 2 are closed. Of the trials that contain HLA-A*02:01 Positive and ovarian carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 2 are phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is altered in 0.06% of breast carcinoma patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain HLA-A*02:01 Positive and breast carcinoma as inclusion criteria, 4 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 5 clinical trials for cervical carcinoma, of which 3 are open and 2 are closed. Of the trials that contain HLA-A*02:01 Positive and cervical carcinoma as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 3 are phase 1/phase 2 (2 open) [5].

HLA-A*02:01 Positive is altered in 0.06% of cancer patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 4 clinical trials for cancer, of which 3 are open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and cancer as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 4 clinical trials for myelodysplastic syndromes, of which 4 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 4 clinical trials for myxoid liposarcoma, of which 3 are open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and myxoid liposarcoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 3 clinical trials for esophageal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and esophageal carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 3 clinical trials for fallopian tube carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and fallopian tube carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 3 clinical trials for oropharyngeal squamous cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain HLA-A*02:01 Positive and oropharyngeal squamous cell carcinoma as inclusion criteria, 3 are phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and primary peritoneal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and soft tissue sarcoma as inclusion criteria, 3 are phase 1 (2 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for acute biphenotypic leukemia, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for anal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and anal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for bone sarcoma, of which 1 is open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and bone sarcoma as inclusion criteria, 2 are phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for chronic myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and gastric carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 3 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for lymphoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for malignant thyroid gland neoplasm, of which 0 are open and 2 are closed. Of the trials that contain HLA-A*02:01 Positive and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].

HLA-A*02:01 Positive is altered in 0.24% of mesothelioma patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for mesothelioma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for oropharyngeal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and oropharyngeal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for penile carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and penile carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for round cell liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and round cell liposarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for uveal melanoma, of which 2 are open and 0 are closed. Of the trials that contain HLA-A*02:01 Positive and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for vaginal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and vaginal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 2 clinical trials for vulvar carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HLA-A*02:01 Positive and vulvar carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for anal canal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and astrocytoma as inclusion criteria, 1 is phase 3 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for cervical intraepithelial neoplasia, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*02:01 Positive and cervical intraepithelial neoplasia as inclusion criteria, 1 is phase 1 (0 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is altered in 0.05% of colorectal carcinoma patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is altered in 0.07% of glioma patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is altered in 0.1% of lung carcinoma patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for malignant ovarian germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and malignant ovarian germ cell tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is altered in 0.34% of malignant pleural mesothelioma patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for malignant pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*02:01 Positive and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for meningioma, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*02:01 Positive and meningioma as inclusion criteria, 1 is phase 2 (0 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for Merkel cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and Merkel cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and myeloproliferative neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for ovarian granulosa cell tumor, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and ovarian granulosa cell tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for ovarian sarcoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and ovarian sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for primary peritoneal serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

HLA-A*02:01 Positive is altered in 0.12% of sarcoma patients [4].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains HLA-A*02:01 Positive and sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for vulvar high grade squamous intraepithelial lesion, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*02:01 Positive and vulvar high grade squamous intraepithelial lesion as inclusion criteria, 1 is phase 1 (0 open) [5].

HLA-A*02:01 Positive is an inclusion criterion in 1 clinical trial for vulvar squamous intraepithelial lesion, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*02:01 Positive and vulvar squamous intraepithelial lesion as inclusion criteria, 1 is phase 2 (0 open) [5].